This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

WILLIAM M. M. KIRBY, M.D.; TRYGVE FORLAND, M.D.; FRANCIS M. MAPLE, M.D.

AMA Arch Intern Med. 1953;92(4):464-470.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

FROM THE standpoint of antibiotic therapy, infections caused by staphylococci constitute one of the major problems at the present time. In hospitalized patients approximately 70% of staphylococcic infections are caused by penicillin-resistant organisms and 40 to 60% are resistant to chlortetracycline (aureomycin) and oxytetracycline.¹ In many instances, the only antibiotics available for treatment are bacitracin and chloramphenicol, both of which must be administered with caution because of possible toxic reactions.

In vitro studies indicate that a new antibiotic, erythromycin, should be a highly effective agent for the therapy of staphylococcic infections. To date, only isolated case reports have appeared.² During the past several months we have had the opportunity of observing the effects of erythromycin therapy in 34 patients with infections caused by antibiotic-resistant staphylococci. Results of treatment were uniformly good and will be described in the present report.

PLAN OF STUDY

Selection of Patients.

—Thirty-four patients with . . . [Full Text PDF of this Article]

Author Affiliations
SEATTLE

From the Departments of Medicine and Surgery, University of Washington School of Medicine, and the King County Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?